YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
GAITHERSBURG, Md., Jan. 22, 2024 /PRNewswire/ — YS Biopharma Co., Ltd. (NASDAQ: YS) (“YS Biopharma”) along with its subsidiaries (“YS Group” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its unaudited consolidated financial results for the first half of the fiscal year ended March 31, 2024 (the “first half of fiscal year 2024”).
Related news for (YS)
- Energy Fuels Announces Closing of Upsized US$700.0 Million Convertible Senior Notes Offering and Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes
- Azitra Receives Notice of Non-Compliance from NYSE American
- New Pacific Metals Files Base Shelf Prospectus to Replace Expired Shelf Prospectus
- Metallus and United Steelworkers (USW) Local 1123 Reach Tentative Agreement for New Four-Year Contract
- Community Healthcare Trust Announces Third Quarter Earnings Release Date And Conference Call